GABA Therapeutics Completed Phase 1 Etifoxine in Melbourne
GABA Therapeutics has continued to progress the development of GRX-917 without any material impact from the COVID-19 pandemic. GABA Therapeutics recently completed its Phase 1 clinical trial of the anxiolytic etifoxine in Melbourne, Australia, on time and slightly ahead of budget. The two-stage, double-blind, placebo-controlled single and multiple dose [...]